PH26690A - Method for treating dysuria using naftpidil - Google Patents
Method for treating dysuria using naftpidil Download PDFInfo
- Publication number
- PH26690A PH26690A PH40616A PH40616A PH26690A PH 26690 A PH26690 A PH 26690A PH 40616 A PH40616 A PH 40616A PH 40616 A PH40616 A PH 40616A PH 26690 A PH26690 A PH 26690A
- Authority
- PH
- Philippines
- Prior art keywords
- naftopidil
- patient
- dysuria
- naftpidil
- administered
- Prior art date
Links
- 206010013990 dysuria Diseases 0.000 title claims abstract description 6
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 229950005705 naftopidil Drugs 0.000 claims description 7
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 5
- 201000004240 prostatic hypertrophy Diseases 0.000 claims description 4
- 206010020880 Hypertrophy Diseases 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 230000027939 micturition Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3918543A DE3918543A1 (de) | 1989-06-07 | 1989-06-07 | Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26690A true PH26690A (en) | 1992-09-15 |
Family
ID=6382247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH40616A PH26690A (en) | 1989-06-07 | 1990-05-04 | Method for treating dysuria using naftpidil |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5026706A (cs) |
| EP (1) | EP0401653B1 (cs) |
| JP (1) | JPH062673B2 (cs) |
| KR (1) | KR0131452B1 (cs) |
| AT (1) | ATE84416T1 (cs) |
| AU (1) | AU625766B2 (cs) |
| CA (1) | CA2017619C (cs) |
| DD (1) | DD294864A5 (cs) |
| DE (2) | DE3918543A1 (cs) |
| DK (1) | DK0401653T3 (cs) |
| ES (1) | ES2054147T3 (cs) |
| GR (1) | GR3007328T3 (cs) |
| HK (1) | HK46996A (cs) |
| HU (1) | HU206976B (cs) |
| IE (1) | IE62937B1 (cs) |
| IL (1) | IL94601A (cs) |
| PH (1) | PH26690A (cs) |
| PT (1) | PT94268B (cs) |
| ZA (1) | ZA904338B (cs) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254469B (it) * | 1992-02-25 | 1995-09-25 | Recordati Chem Pharm | Derivati benzopiranici e benzotiopiranici |
| US5474994A (en) * | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
| US6054432A (en) * | 1996-09-12 | 2000-04-25 | Asta Medica Aktiengesellschaft | Means for treating prostate hypertrophy and prostate cancer |
| TW536402B (en) | 1998-06-26 | 2003-06-11 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition for the therapy of voiding dysfunction |
| DE60045751D1 (de) | 1999-09-30 | 2011-04-28 | Harbor Biosciences Inc | Therapeutische Behandlung androgenrezeptorbedingter Leiden |
| JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
| BR102012000187A2 (pt) * | 2012-01-05 | 2018-04-10 | Univ Rio De Janeiro | Derivados n-fenilpiperazínicos antagonistas de adrenoceptores a1a, a1d e de receptores 5-ht1a no tratamento da hiperplasia prostática benigna, composições farmacêuticas contendo os mesmos |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL175059C (nl) * | 1974-02-23 | Boehringer Mannheim Gmbh | Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten. |
-
1989
- 1989-06-07 DE DE3918543A patent/DE3918543A1/de active Granted
-
1990
- 1990-05-04 PH PH40616A patent/PH26690A/en unknown
- 1990-05-28 CA CA002017619A patent/CA2017619C/en not_active Expired - Lifetime
- 1990-05-30 ES ES90110207T patent/ES2054147T3/es not_active Expired - Lifetime
- 1990-05-30 EP EP90110207A patent/EP0401653B1/de not_active Expired - Lifetime
- 1990-05-30 US US07/530,362 patent/US5026706A/en not_active Expired - Lifetime
- 1990-05-30 AT AT90110207T patent/ATE84416T1/de not_active IP Right Cessation
- 1990-05-30 DE DE9090110207T patent/DE59000748D1/de not_active Expired - Fee Related
- 1990-05-30 DK DK90110207.9T patent/DK0401653T3/da active
- 1990-06-01 JP JP2144272A patent/JPH062673B2/ja not_active Expired - Lifetime
- 1990-06-03 IL IL9460190A patent/IL94601A/en unknown
- 1990-06-05 PT PT94268A patent/PT94268B/pt not_active IP Right Cessation
- 1990-06-05 AU AU56282/90A patent/AU625766B2/en not_active Ceased
- 1990-06-06 HU HU903515A patent/HU206976B/hu not_active IP Right Cessation
- 1990-06-06 ZA ZA904338A patent/ZA904338B/xx unknown
- 1990-06-06 IE IE201490A patent/IE62937B1/en not_active IP Right Cessation
- 1990-06-06 DD DD90341372A patent/DD294864A5/de not_active IP Right Cessation
- 1990-06-07 KR KR1019900008320A patent/KR0131452B1/ko not_active Expired - Fee Related
-
1993
- 1993-03-12 GR GR920403077T patent/GR3007328T3/el unknown
-
1996
- 1996-03-14 HK HK46996A patent/HK46996A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA904338B (en) | 1991-03-27 |
| DK0401653T3 (da) | 1993-03-29 |
| HUT54494A (en) | 1991-03-28 |
| HK46996A (en) | 1996-03-22 |
| EP0401653A2 (de) | 1990-12-12 |
| ES2054147T3 (es) | 1994-08-01 |
| IL94601A (en) | 1994-06-24 |
| HU206976B (en) | 1993-03-01 |
| IL94601A0 (en) | 1991-04-15 |
| AU5628290A (en) | 1990-12-13 |
| DD294864A5 (de) | 1991-10-17 |
| PT94268B (pt) | 1997-01-31 |
| CA2017619C (en) | 1995-06-20 |
| US5026706A (en) | 1991-06-25 |
| PT94268A (pt) | 1991-02-08 |
| HU903515D0 (en) | 1990-10-28 |
| DE3918543C2 (cs) | 1991-06-06 |
| ATE84416T1 (de) | 1993-01-15 |
| DE59000748D1 (de) | 1993-02-25 |
| IE62937B1 (en) | 1995-03-08 |
| DE3918543A1 (de) | 1990-12-13 |
| KR910000152A (ko) | 1991-01-29 |
| GR3007328T3 (cs) | 1993-07-30 |
| JPH062673B2 (ja) | 1994-01-12 |
| CA2017619A1 (en) | 1990-12-07 |
| EP0401653B1 (de) | 1993-01-13 |
| EP0401653A3 (de) | 1991-07-17 |
| JPH0324014A (ja) | 1991-02-01 |
| KR0131452B1 (ko) | 1998-04-17 |
| IE902014L (en) | 1990-12-07 |
| AU625766B2 (en) | 1992-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chow et al. | Efficacy of antifungal agents in tissue conditioners in treating candidiasis | |
| Yalin et al. | Strontium ranelate treatment improves oxidative damage in osteoporotic rat model | |
| NO975439L (no) | Ketonderivater og medisinsk anvendelse derav | |
| JP2003510243A (ja) | 分子ヨウ素経口投与のための方法および医薬組成物 | |
| NO823638L (no) | Fremgangsmaate ved fremstilling av terapeutisk virksomme hydroxysubstituerte 2-benzothiazolsulfonamider | |
| TW200838549A (en) | Methods for preventing and treating neurodegenerative disorders | |
| Pandarathodiyil et al. | Angular cheilitis-an updated overview of the etiology, diagnosis, and management | |
| Garner et al. | Nanoparticles for controlled delivery and sustained release of chlorhexidine in the oral environment | |
| PH26690A (en) | Method for treating dysuria using naftpidil | |
| Mohammad et al. | Clinical and microbiological efficacy of chlorine dioxide in the management of chronic atrophic candidiasis: an open study | |
| Akar, H Bülent Taştan, Hakan Erbil, Ercan Arca, Zafer Kurumlu, Ali Rıza Gür | Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses | |
| Salim | Removing oxygen-derived free radicals delays hepatic metastases and prolongs survival in colonic cancer: a study in the rat | |
| Rajalingam et al. | Anti-tumour and anti-oxidative potential of diosgenin against 7, 12-dimethylbenz (a) anthracene induced experimental oral carcinogenesis | |
| JPWO2012086760A1 (ja) | 消毒剤 | |
| US5264428A (en) | Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases | |
| Vestergaard et al. | 50 Years with lithium treatment in affective disorders: present problems and priorities | |
| Halpern et al. | The action of promethazine (phenergan) in protecting mice against death due to histamine | |
| US4749719A (en) | Method of treating skin pigmentation abnormalities with pantetheine-S-sulfonic acid | |
| Teanpaisan et al. | Effectiveness of A rtocarpus lakoocha extract, poloxamer 407, on E nterococcus faecalis in vitro | |
| Bengtsson et al. | Enzyme replacement in Anderson-Fabry disease | |
| BR102020024967A2 (pt) | Composição antimicrobiana para uso tópico e/ou externo | |
| NZ245673A (en) | Use of naftopidil [ie 1-(2-methoxyphenyl)-4-[3-(naphth-1-yloxy)-2-hydroxypropyl]piperazine] to prepare a medicament for the treatment of dysuria | |
| Usiobeigbe et al. | Effects of Stone Herbal Mixture on Antioxidant Levels | |
| Usiobeigbe et al. | Journal of Medical Care Research and Review | |
| Mitchell et al. | Vitamin D and tuberculosis |